Analysts are skeptical of the massive 30-40% gap in 2026 sales projections between Eli Lilly (+25%) and Novo Nordisk (-5% to -13%). Given that the two companies are "joined at the hip" in the GLP-1 market, such a dramatic divergence in financial trajectory is considered highly improbable by some observers.

The metabolic disease market is seeing intense innovation beyond standard injectables. Structure Therapeutics' oral GLP-1 agonist showed efficacy comparable to injections in Phase 2, while Novo Nordisk's triple agonist demonstrated superior results to semaglutide, signaling a multi-pronged assault on current market leaders.

Despite their obesity drugs having similar clinical efficacy—both help patients lose 15-20% of body weight—Eli Lilly's market cap has skyrocketed while Novo Nordisk's has been flat. This massive valuation gap suggests investor narrative and perceived safety profiles are dramatically outweighing the fundamental product similarities.

The obesity drug market is seeing prices cut in half much faster than anticipated, despite being a duopoly. This rapid price degradation is driven by Novo Nordisk, the market laggard, aggressively using price as a weapon to reclaim market share from Eli Lilly, a dynamic typically seen only after multiple new players enter.

Novo priced the maintenance dose of its oral Wegovy pill far lower than anticipated. This aggressive strategy, costing less than the average U.S. monthly grocery bill (~$400), is a direct attempt to regain momentum from rival Eli Lilly and expand the self-pay market before more oral competitors launch.

The transition to oral GLP-1 therapies is a significant market expander, not just a convenience upgrade. Nearly 80% of patients starting oral medications are new to the drug category, indicating a substantial increase in the addressable patient pool rather than simple conversion of existing users.

Eli Lilly’s astronomical growth is also a forecasting challenge. The company significantly undershot its own sales projections, with its CEO admitting the obesity market is a unique "learning experience." This highlights that demand for GLP-1 drugs represents not just market capture, but the creation of an entirely new, rapidly expanding, and unpredictable market.

Eli Lilly's oral GLP-1 is proving to be a market expander, not just a cannibalizer of injectables. An overwhelming 80% of its users are new to the GLP-1 class, driven by an aggressive direct-to-consumer (DTC) telehealth strategy. This signals a vast, untapped patient population for oral obesity treatments.

While Europe's Novo Nordisk invented the famous Ozempic GLP-1 drugs, American competitor Eli Lilly captured 60% of the market. Lilly's dominance comes from superior business execution—securing insurance coverage, scaling production, and nailing marketing—proving that operational excellence can outperform initial invention.